Copyright
©The Author(s) 2016.
World J Gastroenterol. Nov 28, 2016; 22(44): 9727-9733
Published online Nov 28, 2016. doi: 10.3748/wjg.v22.i44.9727
Published online Nov 28, 2016. doi: 10.3748/wjg.v22.i44.9727
Figure 3 Effect of Infliximab on proliferation and vitality of colonic cancer cell line CT26: MTT assay.
A: MTT performed without cell pre-treatment; B: MTT performed following 24 h cell pre-incubation with TNFα.
- Citation: Lopetuso LR, Petito V, Zinicola T, Graziani C, Gerardi V, Arena V, Caristo ME, Poscia A, Cammarota G, Papa A, Cufino V, Sgambato A, Gasbarrini A, Scaldaferri F. Infliximab does not increase colonic cancer risk associated to murine chronic colitis. World J Gastroenterol 2016; 22(44): 9727-9733
- URL: https://www.wjgnet.com/1007-9327/full/v22/i44/9727.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i44.9727